Since its discovery in 1921, insulin-replacement options have evolved substantially and now provide us with more physiological, more flexible, and safer alternatives to normalize glycemia and prevent diabetes-related morbidity and mortality. For patients with type 1 diabetes, insulin replacement is the only viable option for both glycemic control and survival.
related needs (prandial insulin replacement) and to correct hyperglycemia (corrective insulin replacement), while intermediate and long-acting insulin formulations are administered to keep blood glucose levels stable in between meals and overnight (basal insulin replacement). The rapid-acting insulin analogs (lispro, aspart, and glulisine) are absorbed more rapidly and have an earlier and higher insulin peak concentration and a shorter duration of action than their non-analog counterpart, soluble human insulin or regular insulin (refer to individual product package inserts). The more physiological absorption profile of rapid-acting insulin analogs should translate into greater patient adherence to proper timing of insulin to mealtimes, as well as fewer post-prandial glycemic excursions (within two hours of the meal) and a lower risk of late-prandial hypoglycemia (four to six hours after the meal). 3 On the other hand, basal insulin analogs (glargine and detemir) tend to be absorbed more slowly and consistently than their non-analog counterpart (NPH insulin), resulting in a longer duration of action and a flatter absorption profile, 4 possibly translating into better 24-hour basal insulin coverage and less risk of hypoglycemia, especially nocturnal hypoglycemia when basal insulin is administered at bedtime. 5, 6 Although insulin analogs are increasingly preferred over their non-analog counterparts because of their more physiological absorption and action profile, cost may force the use of regular and NPH insulin in certain circumstances (for updated information visit www.drugstore.com).
Whereas individuals with type 1 diabetes are dependent on both basal and prandial insulin replacement to optimize glycemic control, in patients with type 2 diabetes insulin therapy is often implemented in a stepwise approach.
The current paradigm for initiating insulin therapy in the patient with type 2 diabetes with elevated A 1c is to start with 10-20 units of basal insulin, usually at night, and gradually adjust the dose based on the morning blood glucose levels and goal. U S E N D O C R I N E D I S E A S E 2 0 0 7 basal/prandial (or basal-bolus) insulin replacement, continuing the basal insulin preparation and adding one or more pre-prandial injections of rapidacting insulin would make better clinical sense. One simple strategy to achieve this could be to start a dose of rapid-acting insulin representing 10% of the current basal dose prior to the culprit meal. 9 Blood glucose levels at bedtime and fasting can then be used to gradually adjust the doses of prandial and basal insulin, respectively (see Figure 1 ).
An increasing number of patients with long-standing type 2 diabetes may require full basal/prandial insulin replacement (basal insulin replacement plus rapid-acting insulin before every meal) to optimize blood glucose control and reduce the long-term risk of vascular complications associated with hyperglycemia. When switching patients to basal/prandial insulin therapy, the total daily insulin dose is usually redistributed into 50% basal insulin and 10-20% as fixed prandial doses before each meal. 10 For more sophisticated patients who are able and willing to learn how to estimate carbohydrate intake, an individualized insulin-to-carbohydrate ratio might provide greater flexibility and less weight gain. 11 A simple weight-based formula that can be used to derive basal and prandial insulin doses is the Miami 4/12 rule.
Basically, divide the patient's weight in kilograms by four to estimate the basal insulin requirement and by 12 to calculate the fixed prandial insulin dose. The final step to proper basal-bolus insulin replacement is to set preprandial blood glucose targets and provide the patient with instructions to correct hyperglycemia (corrective insulin replacement). Dividing 1,700 by the patient's current total daily dose of insulin should yield a number that estimates the expected fall in blood glucose (in mg/dl) per one unit of injected rapid-acting insulin. 12 For example, a patient on 68 units of insulin a day would be given a corrective (supplemental) scale that adds one unit of rapid-acting insulin for every 25mg/dl that the pre-prandial blood glucose is above target (1,700÷68=25). Once basal/prandial insulin therapy is initiated, the treating physician should periodically review the patient's blood glucose profile (as reflected from the self-monitoring blood glucose log) to make the appropriate adjustments to the basal and prandial insulin components of the therapy. The fasting blood glucose value will continue to be used to make adjustments to the basal insulin component. The blood glucose levels before lunch, before dinner, and at bedtime can be used to adjust the morning, noon, and dinner prandial doses, respectively.
The same basal-bolus concepts used for outpatient management of insulinrequiring diabetes can effectively be implemented in the hospital setting. 
